Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120

On March 20, 2026, Citi raised the terms people connected Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating.

On March 18, 2026, Merck’s Animal Health part announced that the FDA approved an expanded statement for Bravecto Quantum successful dogs, adding attraction and power for further tick taxon for up to 12 months with a azygous injection. The product, archetypal approved successful July 2025, remains disposable done licensed veterinarians and continues to screen fleas and aggregate tick infestations.

On March 16, 2026, the institution besides said caller information from its cardio-pulmonary pipeline volition beryllium presented astatine the American College of Cardiology meeting, including results from the Phase 3 CORALreef AddOn proceedings evaluating enlicitide and the Phase 2 CADENCE proceedings evaluating Winrevair.

Earlier successful March, Wells Fargo raised its terms people connected Merck & Co., Inc. (NYSE:MRK) to $150 from $135 and maintained an Overweight rating, stating that Sac-TMT could go “best-in-class” and perchance regenerate chemotherapy crossed respective indications.

Merck & Co., Inc. (NYSE:MRK) develops and markets pharmaceutical and vaccine products crossed a wide scope of therapeutic areas.

While we admit the imaginable of MRK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.